Data / Form D filings / Verastem, Inc.
Verastem, Inc.: Form D filings
Verastem, Inc., a pharmaceuticals company in Needham, MA, filed 7 Form D notices with the SEC between 2011 and 2020. The latest, on March 6, 2020, reports $100 million sold of a $100 million offering to 21 investors.
Find out what Verastem, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 117 KENDRICK STREET, SUITE 500, Needham, MA, 02494
- Phone
- (781) 292-4200
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(c)
- SEC identifier (CIK)
- 1526119
The full lists. Form D filings in Massachusetts: 1,533 rows, $76.65, or the new rows each week for $19 a month. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Mar 6, 2020 | New notice | $100,000,000 | $100,000,000 | $0 | 21 | Feb 27, 2020 | sec.gov |
| Jan 7, 2020 | New notice | $4,829,628 | $4,829,628 | $0 | 4 | Dec 23, 2019 | sec.gov |
| Mar 6, 2014 | New notice | $3,898,326 | $3,898,326 | $0 | 1 | Feb 21, 2014 | sec.gov |
| Jul 19, 2012 | New notice | $2,000,000 | $2,000,000 | $0 | 1 | Jul 11, 2012 | sec.gov |
| Nov 21, 2011 | Amendment | $20,402,606 | $20,402,606 | $0 | 36 | Nov 1, 2011 | sec.gov |
| Nov 10, 2011 | New notice | $20,102,609 | $20,102,609 | $0 | 34 | Nov 1, 2011 | sec.gov |
| Jul 26, 2011 | New notice | $32,050,000 | $32,050,000 | $0 | 23 | Jul 12, 2011 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| BRIAN STUGLIK | Executive Officer, Director | |
| BRUCE WENDEL | Director | |
| ERIC ROWINSKY | Director | |
| ALISON LAWTON | Director | |
| TIMOTHY BARBERICH | Director | |
| MICHAEL KAUFFMAN | Director | |
| DAN PATERSON | Executive Officer | |
| GINA CONSYLMAN | Director | |
| ROB GAGNON | Executive Officer |
Other pharmaceuticals companies in Massachusetts that filed recently
- BridgeHealth Pharmaceuticals, Inc. $3.5 million · Nov 5, 2026
- Land Therapeutics Inc. $17.5 million · Oct 21, 2026
- Crosslink Therapeutics Inc. $5.5 million · Oct 20, 2026
- Sentonix, Inc. $12.7 million · Aug 20, 2026
Every Form D from the week of Mar 2, 2020 · All recent filings in Massachusetts · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Verastem, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.